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Abstract 
 Lipocalin-type prostaglandin D synthase (L-PGDS) catalyzes the isomerisation of the 9,11-
endoperoxide group of PGH2 (Prostaglandin H2) to produce PGD2 (Prostaglandin D2) with 9-
hydroxy and 11-keto groups in the presence of sulphydryl compounds. PGH2 is a common precursor 
of all prostanoids, which include thromboxanes, prostacyclins and prostaglandins. PGD2 is 
synthesized in both the central and peripheral nervous system and it is involved in many regulatory 
events. L-PGDS, the first member of the important lipocalin family to be recognized as an enzyme, is 
also able to bind and transport small hydrophobic molecules and was formerly known as β-trace 
protein, the second most abundant protein in human cerebro-spinal fluid. L-PGDS is also detected in 
brain, testis and prostate, endothelial cells, placenta and heart tissue and even in macrophages 
infiltrated in atherosclerotic plaques. In these tissues it participates in many physiological activities 
as well as in the response to diseases. In this work we use recombinant human L-PGDS in order to 
solve its three-dimensional structure by X-ray diffraction and test its affinity for several ligands using 
Surface Plasmon Resonance (SPR). Wild type human L-PGDS and three mutants (C65A; C65A-
K59A; C89/186A) were expressed using E. coli cell strains and subsequently purified by a chitin 
affinity column, size exclusion and hydrophobic interaction chromatography. Large and highly 
ordered crystals were used to collect X-ray diffraction data using either a rotating-anode generator or 
a synchrotron source. The multiple isomorphous replacement method was used to solve the phase 
problem. In the electron density maps an unidentified density was observed apparently interacting 
with lysine 59 inside the L-PGDS-C65A cavity; the foreign molecule could be PEG, an additive 
present in the crystallization liquors. This hypothesis is supported by the fact that the L-PGDS-
C65A/K59A crystals, which grow without PEG, show a completely free protein cavity. A seeding 
experiment of L-PGDS-C65A/K59A crystal, grown in L-PGDS-C65A crystallization conditions, 
partially confirmed this hypothesis since the foreign molecule was present in the L-PGDS-
C65A/K59A cavity. Another molecule that can explain this foreign density is triacontyl acetate, that 
can be present in the Luria Bertani medium used to growth E. coli cells. We are currently trying to 
establish the identity of the unknown ligand. Another crystal form was obtained by mixing L-PGDS-
C65A/K59A with the amyloid β peptide (1-40). Although the amyloid β peptide is not visible in the 
maps, the packing of the protein molecules was changed in the presence of the peptide suggesting 
interaction of the two molecules. Wild type L-PGDS small crystals were recently obtained and will 
be tested as soon as synchrotron beam time becomes available.  
 SPR experiments are also in progress and will be used to verify the interaction of L-PGDS with 
PEG, triacontyl acetate, the amyloid β peptide and other ligands and to determine their binding 
constants. 
 
